1. HBW Insight
  2. >>Archive

Audio Feature: FDA Monitoring Cosmetic Claims, But Litigation Remains Biggest Threat

 
• By Ryan Nelson

Attorney Steven Shapiro, a partner at Ullman, Shapiro & Ullman, LLP, offers perspective on what he considers some of the biggest challenges cosmetics companies face in the current regulatory and legal landscape, specifically when it comes to crafting claims. Story features audio clips from the attorney’s interview with “The Rose Sheet.”

FDA has ramped up its enforcement of cosmetic claims that trespass on drug turf, but the most significant threat to businesses continues to be the potential for class actions that frequently piggyback on enforcement actions and other issues brought to the public’s attention, attorney Steve Shapiro says.

A partner at Ullman, Shapiro & Ullman, LLP, Shapiro has more than 27 years of experience in food and drug regulatory matters, focusing on natural product issues in particular

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from HBW Insight

MAHA Translates To ‘Change The Broken System’ At US FDA For Commissioner Makary

 
• By Malcolm Spicer

Among FDA's diversions from accepted practices is not going “through the bureaucracy” of advisory committees for experts’ input on potential changes to improve the safety and nutrition profile of food products, says Commissioner Martin Makary.

Value Of Consumer Wearables Within The Clinic Currently Unknown, Says Cardiologist

 
• By Natasha Barrow

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.